Getein Biotech, Inc (SHA:603387)

Market Cap	4.17B -5.7%
Revenue (ttm)	1.11B +6.9%
Net Income	292.52M +40.1%
EPS	0.58 +41.4%
Shares Out	506.44M
PE Ratio	14.20
Forward PE	n/a
Dividend	0.30 (3.64%)
Ex-Dividend Date	Sep 18, 2026

Volume	11,332,396
Open	8.51
Previous Close	8.55
Day's Range	8.21 - 8.55
52-Week Range	7.37 - 11.42
Beta	0.08
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 28, 2026

About Getein Biotech

Getein Biotech, Inc researches, develops, produces, and sells in vitro diagnostic reagents and instruments in China and internationally. The company provides point-of-care detection, chemiluminescence detection, biochemical analysis, molecular testing, thrombus and hemostasis detection, blood cell analysis detection, urine analysis, quality control products, diagnostic raw materials, biochemical immunity, and other fields, such as myocardium, inflammation, renal function, thyroid function, hormones, glucose metabolism, tumor, coagulation, blood...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2002
• Employees: 1,733
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 603387

Financial Performance

In 2025, Getein Biotech's revenue was 1.05 billion, a decrease of -9.71% compared to the previous year's 1.16 billion. Earnings were 220.66 million, a decrease of -1.33%.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Nov 13, 2026

Data Sources Report a data error